CA2421842A1 - Antibody and/or chemokine constructs which bind to a chemokine receptor and their use in immunological disorders - Google Patents

Antibody and/or chemokine constructs which bind to a chemokine receptor and their use in immunological disorders Download PDF

Info

Publication number
CA2421842A1
CA2421842A1 CA002421842A CA2421842A CA2421842A1 CA 2421842 A1 CA2421842 A1 CA 2421842A1 CA 002421842 A CA002421842 A CA 002421842A CA 2421842 A CA2421842 A CA 2421842A CA 2421842 A1 CA2421842 A1 CA 2421842A1
Authority
CA
Canada
Prior art keywords
chemokine
antibody
cells
construct
ccr5
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002421842A
Other languages
English (en)
French (fr)
Inventor
Matthias Mack
Detlef Schloendorff
Michael Spring
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Research Munich GmbH
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/948,004 external-priority patent/US6723538B2/en
Application filed by Individual filed Critical Individual
Publication of CA2421842A1 publication Critical patent/CA2421842A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/521Chemokines
    • C07K14/523Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77Internalization into the cell
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
CA002421842A 2000-09-08 2001-09-10 Antibody and/or chemokine constructs which bind to a chemokine receptor and their use in immunological disorders Abandoned CA2421842A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP00119694.8 2000-09-08
EP00119694 2000-09-08
US09/948,004 US6723538B2 (en) 1999-03-11 2001-09-05 Bispecific antibody and chemokine receptor constructs
US09/948,004 2001-09-05
PCT/EP2001/010433 WO2002020615A2 (en) 2000-09-08 2001-09-10 Antibody and/or chemokine constructs which bind to a chemokine receptor and their use in immunological disorders

Publications (1)

Publication Number Publication Date
CA2421842A1 true CA2421842A1 (en) 2002-03-14

Family

ID=32842663

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002421842A Abandoned CA2421842A1 (en) 2000-09-08 2001-09-10 Antibody and/or chemokine constructs which bind to a chemokine receptor and their use in immunological disorders

Country Status (10)

Country Link
EP (1) EP1317284A2 (ja)
JP (1) JP2004508036A (ja)
AU (1) AU2002212225A1 (ja)
CA (1) CA2421842A1 (ja)
HU (1) HUP0300942A2 (ja)
NO (1) NO20031070L (ja)
PL (1) PL366062A1 (ja)
RU (1) RU2252786C2 (ja)
WO (1) WO2002020615A2 (ja)
ZA (1) ZA200301890B (ja)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4090348A1 (en) * 2020-01-13 2022-11-23 The Regents of The University of California Methods for treating viral infections

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002360073A1 (en) * 2001-12-21 2003-07-09 Micromet Ag Mono-and dual chemokine/cytokine constructs
EP2336179A1 (en) 2002-11-08 2011-06-22 Ablynx N.V. Stabilized single domain antibodies
EP1937311A2 (en) 2005-09-30 2008-07-02 The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services Methods and compositions for modulating immune tolerance
NZ575163A (en) 2006-08-28 2011-12-22 Jolla Inst Allergy Immunolog Antagonistic human light-specific human monoclonal antibodies
AR065369A1 (es) 2007-02-19 2009-06-03 Novartis Ag Derivados de ciclohexil - amida del acido aril- carboxilico
SG10201407388XA (en) 2007-08-29 2015-01-29 Sanofi Aventis Humanized anti-cxcr5 antibodies, derivatives thereof and their uses
DK2585089T3 (en) * 2010-06-28 2016-12-12 Universitätsklinikum Freiburg CCL18 blockade of signaling through CCR6 as a therapeutic option in fibrotic diseases and cancer
EP4303236A3 (en) 2010-11-30 2024-03-20 Chugai Seiyaku Kabushiki Kaisha Cytotoxicity-inducing therapeutic agent
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
CA2943943C (en) 2014-04-07 2023-01-10 Chugai Seiyaku Kabushiki Kaisha Immunoactivating antigen-binding molecule
SG11201609370QA (en) 2014-05-13 2016-12-29 Chugai Pharmaceutical Co Ltd T cell-redirected antigen-binding molecule for cells having immunosuppression function
US11660340B2 (en) 2015-11-18 2023-05-30 Chugai Seiyaku Kabushiki Kaisha Combination therapy using T cell redirection antigen binding molecule against cell having immunosuppressing function
US11649293B2 (en) 2015-11-18 2023-05-16 Chugai Seiyaku Kabushiki Kaisha Method for enhancing humoral immune response
WO2017210749A1 (en) * 2016-06-10 2017-12-14 Adelaide Research & Innovation Pty Ltd Methods and products for treating autoimmune diseases
CN109970856B (zh) 2017-12-27 2022-08-23 信达生物制药(苏州)有限公司 抗lag-3抗体及其用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000004926A2 (en) * 1998-07-22 2000-02-03 Osprey Pharmaceuticals Limited Conjugates for treating inflammatory disorders and associated tissue damage
ATE286074T1 (de) * 1999-03-11 2005-01-15 Micromet Ag Gegen ccr5 gerichtete antikörperkonstrukte und ihre verwendung in der behandlung von autoimmunkrankheiten

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4090348A1 (en) * 2020-01-13 2022-11-23 The Regents of The University of California Methods for treating viral infections
EP4090348A4 (en) * 2020-01-13 2024-05-15 The Regents of The University of California METHODS FOR TREATING VIRAL INFECTIONS

Also Published As

Publication number Publication date
ZA200301890B (en) 2004-03-16
EP1317284A2 (en) 2003-06-11
NO20031070L (no) 2003-05-06
WO2002020615A3 (en) 2002-07-25
JP2004508036A (ja) 2004-03-18
RU2252786C2 (ru) 2005-05-27
HUP0300942A2 (hu) 2003-09-29
WO2002020615A2 (en) 2002-03-14
AU2002212225A1 (en) 2002-03-22
NO20031070D0 (no) 2003-03-07
PL366062A1 (en) 2005-01-24

Similar Documents

Publication Publication Date Title
US6723538B2 (en) Bispecific antibody and chemokine receptor constructs
JP6845177B2 (ja) 長寿命ポリペプチド結合分子
RU2228202C2 (ru) Cd19xcd3-специфические полипептиды и их применение
JP6811723B2 (ja) 多価ヒト免疫不全ウイルス抗原結合分子およびその使用方法
RU2733496C2 (ru) Триспецифические связывающие молекулы для лечения вирусной инфекции гепатита в и связанных состояний
CA2421842A1 (en) Antibody and/or chemokine constructs which bind to a chemokine receptor and their use in immunological disorders
TW201326214A (zh) Bcma及cd3結合分子
TW202340257A (zh) 雙特異性抗體
JP2019514871A (ja) 骨髄性白血病の治療方法で使用するための、cd33とcd3に結合する二重特異性構築物の投与の方法
JP2024511465A (ja) Nk細胞エンゲージングのためにサイトカインに融合したnkp46結合性部位、がん抗原結合性部位を含む多特異性タンパク質
US11384156B2 (en) Adoptive T-cell therapy using EMPD-specific chimeric antigen receptors for treating IgE-mediated allergic diseases
JP2023539524A (ja) エンゲージャを含む薬物治療剤の開発及び応用
TW202102544A (zh) 雙特異性抗體
JP2022523009A (ja) 脱免疫化志賀毒素aサブユニットエフェクターを含むcd38結合性タンパク質
WO1999061629A1 (fr) Dispositif pour la separation cellulaire et procede de separation
CN109957012B (zh) 抗h7n9全人源单克隆抗体8e17及其制法与应用
CN109957011B (zh) 抗h7n9全人源单克隆抗体6e9及其制法与应用
EP3366704A1 (en) Antibodies specific for mmp1/hla-a2 complex
EP1456241B1 (en) Mono-and dual anti-cd4-rantes chemokine/cytokine constructs
JP2018138022A (ja) ヒトIgG1 Fc領域変異体およびその使用
WO2023110937A1 (en) Depletion of nk cells for the treatment of adverse post-ischemic cardiac remodeling
JP2023548345A (ja) クリッピング率の低減した抗原結合ドメイン

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued